PK of Lefradafiban with Pantoprazole in Healthy Subjects

Phase 1, randomised, open-label trial of lefradafiban in unstable angina (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma at steady state, 13th dosing interval up to 168 hours, Maximum concentration of the analyte in plasma at steady state, 13th dosing interval up to 168 hours and 2 more. Started Apr 1998; status: completed.